SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report

Report for Clinical Trial NCT00830245

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis

NCT00830245 Leptomeningeal Carcinomatosis Non-small Cell Lung Cancer
MeSH: Lung Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma Meningeal Carcinomatosis
HPO: Carcinoma Neoplasm of the lung Non-small cell lung carcinoma

1 Interventions

Name: Erlotinib

Description: Erlotinib 150mg/day

Type: Drug

Erlotinib

Primary Outcomes

Measure: Overall survival

Time: 1 year

Secondary Outcomes

Measure: Cytology negative conversion rate

Time: 1 month, 2 months, 3 months, 4 months

Measure: Neurologic symptom improvement

Time: 1 month, 2 months, 3 months, 4 months

Measure: Response rate (extra-cranial disease)

Time: 2 months, 4 months

Measure: Response rate (brain)

Time: 2 months, 4 months

Measure: Quality of life

Time: 1 month, 2 months, 3 months, 4 months

Measure: Toxicities

Time: 1 month, 2 months, 3 months, 4 months

Measure: Prognostic factors

Time: N-A
Purpose: Treatment

Allocation: Non-Randomized

Single Group Assignment

There is one SNP

SNPs

1 L858R

Inclusion Criteria: 1. Age >18 2. Histologically or pathologically proven non-small cell lung cancer (NSCLC) 3. Leptomeningeal carcinomatosis confirmed by CSF cytology 4. A patients with EGFR mutation (including exon 19 deletion, L858R) 5. ECOG performance status 0-3 6. Expected life time more than at least 4 weeks 7. --- L858R ---

A patient who refused to sign the informed consent Inclusion Criteria: 1. Age >18 2. Histologically or pathologically proven non-small cell lung cancer (NSCLC) 3. Leptomeningeal carcinomatosis confirmed by CSF cytology 4. A patients with EGFR mutation (including exon 19 deletion, L858R) 5. ECOG performance status 0-3 6. Expected life time more than at least 4 weeks 7. --- L858R ---


HPO Nodes

HPO:
Carcinoma
Genes 11
PTEN CDKN1B APC MLH1 MSH2 FGFR3 KIT DKC1 RSPO1 STK11 NLRP1
Neoplasm of the lung
Genes 43
WT1 KRAS SLC22A18 STK11 IRF1 AKT1 C11ORF95 PRKN PPP2R1B ERBB2 TRPV3 TSC1 POU6F2 TSC2 EWSR1 RELA KEAP1 REST DIS3L2 SFTPA2 GPC3 MBTPS2 LMNA PTEN BRAF BRCA2 EGFR RB1 TRIP13 PDGFRB TERT SFTPC PIK3CA TRIM28 DICER1 MAP3K8 HPGD SLCO2A1 H19 TP53 NOTCH3 BAP1 WRN
Non-small cell lung carcinoma
Genes 2
TP53 BAP1